Since 2008 before the spin-off from SK chemicals, we focused on premium vaccines as new-driving forces for growth.
We continued to invest in production and manufacturing infrastructure.
As a result of these efforts, we have achieved significant accomplishments,
including launching of the first Korean cell culture-based trivalent influenza vaccine in 2015,
followed by the world first cell culture-based quadrivalent influenza vaccine, the world second shingles vaccine, and the Korea's second varicella vaccine.
Based on our excellent vaccine research capabilities, we are jointly developing the next-generation pneumococcal vaccine with global biotech company, Sanofi Pastuer.
Since 2020, SK bioscience is preparing an advance into the global market through
not just co-development of the Korea's first COVID-19 vaccine with global initiatives, but also CDMO/CMO with global vaccine developers.
- Acquired Dongshin Pharm (2001)
- Established Vaccine R&D Center (2005)
- Headquarters in Pangyo
- Established L HOUSE
(Vaccine Plant in Andong)
- Established SK bioscience (2018)
Subsidiaries of SK Group
Subsidiaries of SK Group strive to achieve growth and development via the “separately and together” strategy. Each subsidiary not only promotes enhancement of business competitiveness and maximization of enterprise value through autonomous and responsible management, but also spontaneously collaborates with other subsidiaries to create greater value.
SK Discovery has highly competitive businesses in eco-friendly materials, vaccines, pharmaceuticals, energy/chemicals, and real estate development. All our employees are committed to enhancing the business competitiveness of our subsidiaries and increasing shareholder value by establishing a foundation for continuous growth through efficient management and financial stability.
Originally established as Sunkyong Fibers Ltd. in 1969, SK CHEMICALS has been leading the innovation and change in chemicals and life science in Korea. SK Chemicals set itself the mission to “promote human health and protect the environment” and reorganized the business structure to focus on two pillars: “Green Chemicals” and “Life Science.” With the goal “to become a global leader in eco-friendly materials and total healthcare solutions,” the pharmaceutical giant provides chemicals and life science products and solutions that are necessary for humanity.